menu
    • menu
    [{"orgOrder":0,"company":"University Ghent","sponsor":"Commonwealth Scientific and Industrial Research Organisation, Australia | World Health Organization | Institut Pasteur Cambodia | University of Queensland | Fiocruz | University of Nottingham | University of Yaounde 1 | Ivo de Carneri Foundation | Nationa","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University Ghent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Ghent \/ Commonwealth Scientific and Industrial Research Organisation, Australia | World Health Organization | Institut Pasteur Cambodia | University of Queensland | Fiocruz | University of Nottingham | University of Yaounde 1 | Ivo de Carneri Foundation | Nationa","highestDevelopmentStatusID":"11","companyTruncated":"University Ghent \/ Commonwealth Scientific and Industrial Research Organisation, Australia | World Health Organization | Institut Pasteur Cambodia | University of Queensland | Fiocruz | University of Nottingham | University of Yaounde 1 | Ivo de Carneri Foundation | Nationa"},{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Janssen-Cilag","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Janssen-Cilag \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Janssen-Cilag \/ Undisclosed"},{"orgOrder":0,"company":"McGill University Health Centre Research Institute","sponsor":"McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"McGill University Health Centre Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"McGill University Health Centre Research Institute \/ McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research","highestDevelopmentStatusID":"11","companyTruncated":"McGill University Health Centre Research Institute \/ McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research"},{"orgOrder":0,"company":"PATH","sponsor":"Yale University | Noguchi Memorial Institute for Medical Research | Ghana Health Service | HopeXchange Medical Center, Ghana | Kintampo Health Research Centre, Ghana","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"PATH","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PATH \/ Yale University | Noguchi Memorial Institute for Medical Research | Ghana Health Service | HopeXchange Medical Center, Ghana | Kintampo Health Research Centre, Ghana","highestDevelopmentStatusID":"11","companyTruncated":"PATH \/ Yale University | Noguchi Memorial Institute for Medical Research | Ghana Health Service | HopeXchange Medical Center, Ghana | Kintampo Health Research Centre, Ghana"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Undisclosed","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Repos Pharma","sponsor":"Uppsala University | Uppsala University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Repos Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Repos Pharma \/ Uppsala University | Uppsala University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Repos Pharma \/ Uppsala University | Uppsala University Hospital"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Julie Krystal","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mebendazole","moa":"Tubulin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Julie Krystal","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Julie Krystal"}]

    Find Clinical Drug Pipeline Developments & Deals for Mebendazole

    Menu

    Mebendazole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Repos Pharma

                            Country arrow
                            CPhI India
                            Not Confirmed

                            Repos Pharma

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Uppsala University | Uppsala University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Safety and Efficacy Study of Mebendazole on GI Cancer or Cancer of Unknown Origin.

                            Details : ReposMBZ (Mebendazole) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gastrointestinal Neoplasms.

                            Product Name : ReposMBZ

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 14, 2018

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Uppsala University | Uppsala University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PATH

                            Country arrow
                            CPhI India
                            Not Confirmed

                            PATH

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Yale University | Noguchi Memorial Institute for Medical Research | Ghana Health Service | HopeXchange Medical Center, Ghana | Kintampo Health Research Centre, Ghana

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana

                            Details : Mebendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hookworm Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 25, 2017

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Yale University | Noguchi Memorial Institute for Medical Research | Ghana Health Service | HopeXchange Medical Center, Ghana | Kintampo Health Research Centre, Ghana

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Janssen-Cilag

                            Italy arrow
                            CPhI India
                            Not Confirmed

                            Janssen-Cilag

                            Italy arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfa...

                            Details : Mebendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Helminthiasis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 11, 2015

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable...

                            Details : Mebendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2014

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric...

                            Details : Mebendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Helminthiasis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 13, 2014

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Johnson & Johnson Innovative Medicine

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Julie Krystal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

                            Details : Mebendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Astrocytoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 23, 2013

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Julie Krystal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            University Ghent

                            Country arrow
                            CPhI India
                            Not Confirmed

                            University Ghent

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Commonwealth Scientific and Industrial Research Organisation, Australia | World Health Organization | Institut Pasteur Cambodia | University of Queensland | Fiocruz | University of Nottingham | University of Yaounde 1 | Ivo de Carneri Foundation | Nationa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Monitoring the Efficacy of Anthelmintics for the Treatment of Soil Transmitted Helminths P2

                            Details : Mebendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Ascaris lumbricoides.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 23, 2011

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Commonwealth Scientific and Industrial Research Organisation, Australia | World Health Organization | Institut Pasteur Cambodia | University of Queensland | Fiocruz | University of Nottingham | University of Yaounde 1 | Ivo de Carneri Foundation | Nationa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            McGill University Health Centre Research Institute

                            Country arrow
                            CPhI India
                            Not Confirmed

                            McGill University Health Centre Research Institute

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase IV

                            Sponsor : McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of a Deworming Intervention to Improve Early Childhood Growth and Development in Resource-poor Area...

                            Details : Mebendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malnutrition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 15, 2011

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase IV

                            Sponsor : McGill University | Asociacion Civil Selva Amazonica | World Health Organization | Thrasher Research Fund | Canadian Institutes of Health Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Johnson & Johnson

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Johnson & Johnson

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety Study of Mebendazole in Children 2 to 10 Years of Age

                            Details : Mebendazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 02, 2010

                            Lead Product(s) : Mebendazole

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth